ABSTRACT
BACKGROUND & AIMS Metabolic dysfunction-associated steatotic liver disease (MASLD) affects over 25% of the population and currently has no effective treatments. Plasma proteins with causal evidence may represent promising drug targets. We aimed to identify plasma proteins in the causal pathway of MASLD and explore their interaction with obesity.
METHODS We analysed 2,941 plasma proteins in 43,978 European participants from UK Biobank. We performed genome-wide association study (GWAS) for all MASLD-associated proteins and created the largest MASLD GWAS (109,885 cases/1,014,923 controls). We performed Mendelian Randomization (MR) and integrated proteins and their encoding genes in MASLD ranges to identify candidate causal proteins. We then validated them through independent replication, exome sequencing, liver imaging, bulk and single-cell gene expression, liver biopsies, pathway, and phenome-wide data. We explored the role of obesity by MR and multivariable MR across proteins, body mass index, and MASLD.
RESULTS We found 929 proteins associated with MASLD, reported five novel genetic loci associated with MASLD, and identified 17 candidate MASLD protein targets. We identified four novel targets for MASLD (CD33, GRHPR, HMOX2, and SCG3), provided protein evidence supporting roles of AHCY, FCGR2B, ORM1, and RBKS in MASLD, and validated nine previously known targets. We found that CD33, FCGR2B, ORM1, RBKS, and SCG3 mediated the association of obesity and MASLD, and HMOX2, ORM1, and RBKS had effect on MASLD independent of obesity.
CONCLUSIONS This study identified new protein targets in the causal pathway of MASLD, providing new insights into the multi-omics architecture and pathophysiology of MASLD. These findings advise further therapeutic interventions for MASLD.
Competing Interest Statement
The authors declare the following competing interests: S.H., L.C., C.D., C.A.P.M., M.T., R.M., T.M. and J.M.M.H. are full-time employees of Novo Nordisk. T.G.R. was part-time employee of Novo Nordisk during the project running. J.L. is supported by a University of Oxford Novo Nordisk Research Fellowship. N.D. was supported by a University of Oxford Novo Nordisk Research Training Fellowship. The remaining authors declare no competing interests.
Funding Statement
This research is based on data from the MVP, Office of Research and Development, Veterans Health Administration and was supported by award MVP000 (mvp003/028b). MVP MASLD data was generated with Department of Veterans Affairs (VA) funding support (I01-BX003362: K.M.C., P.S.T., and M.V.) with additional support from resources and facilities of the VA Informatics and Computing Infrastructure (VINCI), VA HSR RES 13-457. This publication does not represent the views of the Department of Veterans Affairs or the United States Government. M.V. acknowledges support for this work from the National Institutes of Health (NIH)/National Institute of Diabetes and Digestive and Kidney Diseases, grant R01 DK134575. J.L. is supported by a Novo Nordisk Postdoctoral Fellowship and N.D. through a Novo Nordisk clinical research training fellowship run in partnership with the University of Oxford. The work has been supported by the Medical Research Council (JWT) and by the Oxford NIHR Biomedical Research Centre (JWT).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All participants provided electronically signed informed consent. UK Biobank has approval from the North West Multi-centre Research Ethics Committee, the Patient Information Advisory Group, and the Community Health Index Advisory Group. The current study is a part of UK Biobank project 53639 and 65851.All participants gave full, informed, written consent for the liver biopsy (NHS research ethics reference: 17/WM/0130).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵* Authors share last authorship
Data availability
UK Biobank data are publicly available to bona fide researchers upon application at http://www.ukbiobank.ac.uk/using-the-resource/. Publicly available summary statistics are obtained from https://gwas.mrcieu.ac.uk/, https://www.ebi.ac.uk/gwas/, https://www.gtexportal.org/home/datasets, and https://pan.ukbb.broadinstitute.org. Bulk liver RNA-seq data are available in Gene Expression Omnibus (GEO) under accession GSE135251. SnRNA-seq and scRNA-seq data are available in GEO under accession GSE189175, GSE185477, GSE136103, GSE212837, GSE189600, and GSE192740. Other source of data or web source were clarified in the methods. Relevant detailed results generated in this study were presented in supplementary tables. Clinical data with respect to the liver biopsy samples were assessable through contacting J.W.T.
ABBREVIATIONS
- MASLD
- metabolic dysfunction-associated steatotic liver disease
- NAFLD
- non-alcoholic fatty liver disease
- MASH
- metabolic dysfunction-associated steatohepatitis
- NASH
- non-alcoholic steatohepatitis
- MR
- Mendelian randomization
- MRI-PDFF
- magnetic resonance imaging - estimated proton density fat fraction
- ICD
- International Classification of Diseases
- LC-MS/MS
- liquid chromatography-tandem mass spectrometry
- MSD
- Matrix Spectral Decomposition
- GWAS
- genome-wide association study
- ALT
- alanine aminotransferase
- PheMR
- phenome-wide Mendelian randomization study
- pQTL
- protein quantitative trait locus
- eQTL
- expression quantitative trait locus
- BMI
- body mass index
- VEP
- variant effect predictor
- LOFTEE
- loss-of-function transcript effect estimator
- DEG
- differentially expressed genes
- snRNA-seq
- single nucleus RNA sequence
- scRNA-seq
- single cell RNA sequence
- age2
- age squared
- SNP
- single-nucleotide polymorphism
- NAFL
- non-alcoholic fatty liver
- GRHPR
- Glyoxylate and hydroxypyruvate reductase
- HMOX2
- heme oxygenase 2
- HMOX1
- heme oxygenase 1
- IGF
- insulin-like growth factor
- SCG3
- secretogranin III
- RBKS
- ribokinase
- ORM1
- Orosomucoid 1
- AHCY
- adenosylhomocysteinase
- FCGR2B
- Fc gamma receptor IIb.
